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Abstract
Background: Despite increasing evidence on the relationship between exposure to phthalates and bisphenol A
with allergies and asthma, reports on atopic dermatitis (AD) with these chemicals are few. We assessed the
association between AD symptoms and the exposure to phthalates and bisphenol A and in children.
Methods: We surveyed 18 boys with AD (age 3–7 years) in a day care center in Seoul between May 2009 and April
2010. AD symptoms were recorded by using a daily symptom diary. We collected 460 series of pooled urine twice
a day, in the morning and afternoon, over 230 working days and measured the concentrations of mono–2–ethyl-5-
oxohexyl phthalate (5-oxo-MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (5-OH-MEHP), mono-isobutyl phthalate
(MnBP) and bisphenol A glucuronide (BPAG) in the pooled urine. Logistic regression was used for statistical analysis.
Results: Most phthalate metabolite levels were higher in the morning than in the afternoon (p < 0.0001). There was
seasonal variation in the levels of phthalates and bisphenol A metabolites. Levels of 5-OH-MEHP, MnBP, and BPAG
were highest in summer (p < 0.0001). Manifestation of AD symptoms was associated with an increase in urinary
levels of MnBP (adjusted odds ratio, aOR = 2.85, 95% CI: 1.12-7.26 per 1 μg/L of MnBP) and BPAG (aOR = 1.79, 95%
CI: 0.91-3.52 per 1 μg/L BPAG) on the same day. The levels of MnBP and BPAG in the previous day increased AD
symptoms (aOR = 2.74, 95% CI: 1.21-6.20, for 1 μg/L of MnBP and aOR = 2.01, 95% CI: 1.08-3.74 for 1 μg/L BPAG).
Conclusion: Our results suggest that exposure to phthalates and bisphenol A is associated with aggravation
of AD symptoms in children.
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Highlights
1. Pooled urine can be a useful tool for the long-term
monitoring of chemical exposures in a confined
environment.
2. Phthalates and bisphenol A exposure is related
with the aggravation of atopic dermatitis
symptom in children.
Background
Phthalic acid esters (phthalates) and bisphenol A (BPA)
are widely used endocrine disrupting chemicals (EDCs)
[26, 29]. Phthalates are found in a wide range of indoor
environment, implying that people can be exposed to
phthalates through inhalation and dermal absorption [7].
BPA is commonly used in food or beverage cans, electronic
products, and household products such as water bottles,
baby bottles, dental fillings, and dental sealants [36].
Previous studies reported that PVC flooring in the
parents’ bedrooms was associated with the development
of asthma among preschool children. In addition, effects
of early life phthalate exposure on immunoglobulin E
(IgE) levels can potentially cause atopic dermatitis (AD)
in children in a 10-year cohort [32, 37]. Indoor dust that
* Correspondence: kmaped@skku.edu; hkcheong@skku.edu
3Department of Pediatrics, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul 06351, Republic of Korea
1Department of Social and Preventive Medicine, Sungkyunkwan University
School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 16419,
Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Environmental Health  (2017) 16:24 
DOI 10.1186/s12940-017-0225-5
includes di-2-ethylhexyl phthalate (DEHP) is associated
with wheezing in preschool-aged children [6, 23]. More-
over, another study has reported that higher levels of BBzP
and DiBP in house dust increase OR of atopic dermatitis
among children [2]. During the prenatal period and early
childhood, exposure to BBzP may influence the risk of de-
veloping eczema [19]. The associations between urinary
BPA concentrations and asthma were also addressed in
children from a birth cohort study [10].
Children are especially vulnerable to indoor environ-
mental hazards because they breathe more air per kilo-
gram of body weight than adults [35] and spend a longer
time at indoor facilities such as school, kindergarten, or
day care centers. Recently, human biological monitoring
data showed that the tolerable intake for children has
been exceeded to a considerable degree [41]. Children
showed clearer association of atopic dermatitis with
BBzP and DiBP in house dust than adults [2] and daily
phthalate intakes estimated from urinary phthalate me-
tabolites are higher in children than adults [3].
AD is the most prevalent type of allergic disorder in
early childhood. In Korea, the prevalence of AD in chil-
dren less than 24 months of age has increased from
19.8% in 2003 to 23.8% in 2008 [46]. AD has become
one of the most prevalent health problems of children
from an environmental health perspective. Although
increasing evidence supports that exposure to phthalates
and BPA is linked with allergies and asthma [11, 27, 29,
39], there are still insufficient data about the effect of
exposure to phthalates and BPA on AD symptoms in a
longitudinal study. In this study, we investigated the
associations between daily levels of phthalates and BPA
metabolites in urine and AD symptoms using a time
series analysis.
Methods
Study design and participants
This study was based on a panel study involving a time
series of repeated measurements of health outcome and
exposure. Between May 2009 and April 2010, we
selected a day care center authorized to take care of
children with AD located in the northeast region of
Seoul. It is located near the metro station, but traffic is
relatively sparse. There are no identified sources of
pollution such as factories or incinerators nearby.
Eighteen boys with AD aged 3 to 7 years were re-
cruited for this study. Their mean (standard deviation,
SD) age was 4.3 ± 0.8 years. The diagnosis of AD was
determined according to the Hanifin and Rajka’s diag-
nostic criteria, which requires presence of at least three
of four major features and at least three of 23 minor
features in the physical signs of AD [12] after all
children were examined by a pediatric allergist who
regularly visited the day care center to follow up on the
children's health status. This study was approved by the
Institutional Review Board of Samsung Medical Center
(SMC 2013-04-057). Informed consent was obtained
from the parents of all participating children.
Atopic dermatitis symptoms
A diary was developed to measure the severity of AD
symptoms [20]. The diary included levels of pruritus
during daytime, daily activity schedules, and changes in in-
door environment status (presence of an air conditioner,
ventilator, air cleaner, or humidifier). Daily pruritus level
was assessed using a VAS scale ranging between 0 and 10.
The symptom diary was recorded by teachers who were
trained on the evaluating and recording symptoms prior
to the study. They were instructed to record once a day
for each child with AD. At the end of each week, the
diaries were returned to the research assistant and were
thoroughly scrutinized for any missing or error records.
As we used pooled urine as a whole to measure the
levels of each metabolite for each day, we applied an AD
symptom manifestation rate (ASMR) to evaluate severity
of daily level of AD symptom in group as a matching
measurement of health outcome. The AD symptom is
first classified into two categories: 0 = No AD symptom
or 1 = presence of AD symptoms (pruritus level greater
than 2) for each boy. We then summed the cases with
AD symptom and divided by total number of attendants
to the day care center for each day. The formula for
ASMR is as follows:
AD symptom manifestation rate
¼ Sum of daily AD cases with manifested symptom
Sum of daily AD cases attended in the child care center
Urine collection and chemical analyses
The urine from 18 boys was collected and pooled into a
collecting bottle installed in a boys’ toilet on the same
floor of the daily classroom twice a day during the study
period. We used boys’ urine for the sustainability and
convenience of collection and pooled the collected urine
considering cost-effectiveness, which has been adopted
in previous studies [14–16, 38, 45, 47]. On a daily basis,
individual urine from 18 boys was continuously combined
to make two pools: morning (9:00–11:00 am) and afternoon
(2:00–4:00 pm). The pooled urine was collected by teachers
every morning and afternoon in non-vinyl and non-
polycarbonate containers, frozen immediately, sent to the
laboratory for testing within 1 to 5 h, and stored at below
−70 °C for a maximum of six months before analysis.
The urine samples were analyzed for three phthalates and
one BPA metabolite. We chose mono-n-butyl phthalate
(MnBP) from di(n-butyl) phthalate (DnBP) and BBzP as pri-
mary metabolites and mono-2-ethyl-5-oxohexyl phthalate
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(MEOHP), mono-2-ethyl-5-hydroxyhexyl phthalate
(MEHHP) from di(2-ethylhexyl) phthalate (DEHP), and
bisphenol A glucuronide (BPAG) as secondary metabolites.
The targeted phthalates and BPA metabolites were analyzed
by high performance liquid chromatography (HPLC, Agilent
1200 series, Agilent Technologies, Santa Clara, CA, USA)
with a tandem mass spectrometer (Agilent Triple Quad
6410, Agilent Technologies, Santa Clara, CA, USA) follow-
ing the method published by the Centers for Disease Con-
trol and Prevention Laboratory Procedure Manual [9]
including the quality control system, handling, and analysis
of samples. Internal quality control was performed by ana-
lyzing control urine with known concentrations. External
quality assurance was provided by the German External
Quality Assessment Scheme for Biological Monitoring (G-
EQUAS) in the case of metabolites of phthalates. The limits
of detection were as follows: 0.6 μg/L for MnBP, 0.5 μg/L for
MEOHP, 0.4 μg/L for MEHHP and 0.15 μg/L for BPA.
Statistical analyses
Urine data from children were compared in terms of
metabolite levels of phthalates and BPA between the
urine collected in the morning and afternoon by season
using the geometric mean with geometric standard
error. Because of the skewed distributions, phthalate and
BPA metabolite levels were log-transformed before ana-
lyses. All log-transformed data were normally distributed
and no significant outliers were found.
We considered days with over 50% of ASMR as having
severe AD symptom incidence and days with less than
50% of ASMR as having mild or negligible incidence.
Differences in phthalates and BPA metabolite levels
between the morning and afternoon were examined by
the Student’s t-test. Comparisons of metabolite levels by
season were done by chi-square analysis.
The associations between ASMR and phthalates and
BPA metabolites were analyzed by multiple logistic regres-
sion models. The goodness of fit of a model was assessed
using a likelihood ratio chi-square. We adjusted for daily
temperature, daily relative humidity, and seasonal effects.
The specification of the models was as follows:
Logit P y ¼ 1ð Þ½  ¼ β0 þ β1 metaboliteð Þ þ β2 temperatureð Þ
þ β3 relative humidityð Þ þ β4 seasonð Þ
where y is the daily ASMR and β1 is daily level of each
targeted phthalate and a BPA metabolite. Lag effects of
metabolites of phthalates and BPA on ASMR were esti-
mated up to three days. Unlagged (Lag0) designates the
effect of each targeted metabolite on the current day on
ASMR and Lag1 ~ Lag3 designates the effect of metabol-
ite on 1 to 3 days in advance on ASMR. The significance
level was set at 0.05 as the standard. SAS version 9.3
(SAS Institute, Inc., Cary, NC, USA) was used for all
statistical analyses.
Results
The characteristics of the children with AD symptoms de-
termined in each season were summarized in Table 1.
ASMR at each season (spring, summer, autumn, winter)
were 29.1, 57.2, 53.5, and 56.9%, respectively, highest in
summer and lowest in spring. The difference in the ASMR
was statistically significant between seasons (p < 0.0001).
During the 12 months of the study period, 460 urinary
concentration data points were available, consisting of
230 data points for each morning and afternoon. Figure 1
shows differences in phthalate and BPA metabolite levels
in urine between the morning and afternoon by season.
Phthalate metabolites (MEHHP, MEOHP, and MnBP)
were significantly higher in the morning than in the
afternoon (p < 0.0001) except in summer for MEHHP
and MEOHP. Morning levels of BPAG metabolite were
higher than those of the afternoon in summer and au-
tumn (p < 0.0001), but their differences were less prom-
inent compared to those of the phthalates metabolites.
The geometric mean (GM) (geometric standard devi-
ation (GSD)) of MEOHP, MEHHP and MnBP concentra-
tions for daily average were 71.97 (1.64), 68.11 (1.58)
and 76.02 (1.71) μg/g creatinine at daily average. The
GM (GSD) in the morning were 77.03 (1.83), 72.34
(1.78), 85.97 (1.82) and 3.36 (1.9), μg/g creatinine in the
afternoon were 67.24 (1.41), 64.13 (1.33), 67.23 (1.54)
and 3.09 (2.07) μg/g creatinine for MEOHP, MEHHP,
MnBP and BPA, respectively.
Pearson correlation coefficients among ASMR and
phthalates and BPA metabolites are shown in Table 2. Sec-
ondary metabolites (MEHHP, MEOHP) were significantly
correlated with the primary metabolite (MnBP) (R = 0.71
and 0.77). The secondary metabolites of DEHP (MEHHP
and MEOHP) were strongly correlated with each other
(R = 0.92). All urinary levels of phthalate metabolites,
DEHP and DnBP, were positively correlated with BPAG
levels (R = 0.20, 0.26, and 0.42 for MEHHP, MEOHP,
and MnBP, respectively). There was significant correlation
between the presence of ASMR and MnBP (R = 0.16,
p = 0.0231) and BPAG levels (R = 0.16, p = 0.0243).
Table 3 presents the influence of phthalates and BPA
metabolites on ASMR after controlling for temperature,
humidity, and season. ASMR was significantly associated
with MnBP and BPAG concentrations. Manifestation of
AD symptoms was strongly associated with an increase
of urinary MnBP levels on the same day (adjusted odds
ratio (aOR) = 2.85, 95% CI: 1.12-7.26). There were no
significant relationships between MEOHP, MEHHP, and
BPAG and AD symptoms. In lagged models, the previ-
ous day’s MnBP and BPAG in urine were positively asso-
ciated with ASMR (aOR = 2.74, 2.01, 95% CI: 1.21-6.20,
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1.08-3.74, respectively) and MEOHP levels in urine
two days before were positively associated with ASMR
(aOR = 3.11, 95% CI: 1.01-9.61).
Discussion
We investigated the effects of phthalates and BPA on
manifestation of AD symptoms in children attending a
day care center based on daily measurements over a
year. AD symptoms in children were associated with
phthalates and BPA metabolites. AD symptoms were
strongly associated with MnBP and BPAG in both
unlagged and one day-lagged models with statistical
significance (Table 3).
Previous studies have reported that associations be-
tween MEHP levels, higher-molecular-weight phthalates
such as DEHP, and serum IgE levels in boys are related
to an increase in IgE sensitization [17, 37]. In addition,
MnBP was significantly associated with AD. A subcuta-
neous injection of MEHP increased IgE levels in mice,
and subcutaneous injection of phthalate can aggravate
AD-like skin lesions induced by Dermatophagoides
pteronyssinus in mice [25, 34]. Animal and in vitro stud-
ies suggested a possible role of BPA in the pathogenesis
Table 1 Summary of atopic dermatitis symptoms in each season
Spring Summer Fall Winter Year-round
Days observed 57 53 64 56 230
Daily attendance in child care center (Mean ± SD) 7.2 ± 2.1 5.2 ± 2.0 8.0 ± 2.2 6.0 ± 2.3 6.7 ± 2.4
No. of children per day with atopic dermatitis (Mean ± SD) 2.1 ± 0.9 3.0 ± 1.9 4.6 ± 2.3 3.5 ± 1.6 3.4 ± 2.0
Mean daily ASMR (%)* 29.1 57.2 53.5 56.9 49.5
ba a a a
*p < .0001 by ANOVA between atopic dermatitis symptoms and season
aDuncan’s post hoc multiple comparison for each season in the ANOVA. The difference between Group A and Group B is significant
ASMR: atopic dermatitis symptom manifestation rate
Fig. 1 Geometric mean and standard deviation of metabolites of phthalates and bisphenol A in the morning and afternoon urine by season.
* Significant by the Student’s t-test at p-value = 0.05
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of allergic disease; urinary BPA is significantly associated
with allergic asthma, as it might act as an allergic or
TH2 sensitizer and induce specific IgE responses
(National Health and Nutrition Examination Survey
2005–2006) [36, 44].
The major route of exposure to DEHP and BPA is
dietary intake, and urine levels tend to be lower during
the fresh foods intervention, which implies that phthal-
ate intake can be reduced by avoiding foods packaged,
stored, or heated in plastic containers [28, 31]. Although
dietary ingestion is the primary route of human expos-
ure to BPA, it was detected in most children’s solid and
liquid food, followed by indoor air, hard floor surface
wipe, food preparation surface wipe, and transferable
residue samples [40]. Routes of exposure to phthalates
have multiple pathways and sources. Phthalates were
mostly detected in a wide range of food, particularly
high fat food. Ingestion through house dust and hand–
to-mouth transfer of products was reported in addition
to dermal intake from cosmetics and personal care prod-
ucts [7, 27, 35, 42].
Although most information on exposure to phthalates
has focused on food and water, inhalation intake should
not be neglected. Children spend a large fraction of their
time indoors, and air concentrations of phthalates are
approximately 10 times higher in indoor air than in out-
door air [29]. Not only BBzP, DEHP, and DnBP, but also
DiNP in house dust increase in the dwellings with PVC
wall and floor [1]. Furthermore, the levels of phthalate
metabolites such as BBzP and DEHP in house dust were
associated with PVC flooring, and high concentrations
of DEHP were associated with buildings constructed be-
fore 1960 [8]. Bekö et al. [7] reported that indoor envir-
onmental exposures for diethyl phthalate (DEP), DnBP
and diisobutyl phthalate (DiBP) is meaningful fraction of
total daily intake through inhalation and dermal absorp-
tion in children. For DEP, DnBP and DiBP, exposures to
air and dust in the indoor environment accounted for
approximately 100, 15 and 50% of the total intake,
respectively.
Ait Bamai et al. [3] found the daily phthalate intakes
estimated from urinary metabolites were higher in chil-
dren than their parents. For infants and toddlers, one of
the most important phthalate intake sources is floor
dust. Young children ingest up to 10 times more house
dust than adults, and are therefore more vulnerable to
exposure to phthalates because of their hand-to-mouth
behavior on the flooring [1, 21]. House dust is also well
known to be a main exposure source to allergens and
other EDCs for infants. Similar to indoor air concentra-
tions, levels of phthalates in settled dust have been asso-
ciated with PVC building materials [3, 8]. Yamamoto
[43] found substantial migration of BPA from PVC hoses
into room temperature water. BPA exposure from this
source by ingestion or inhalation deserves consideration
because PVC pipe is approved for use in residential
water supply lines. Hsu et al. [18] examined the home
environment along with bio-monitoring data. They
noted that exposure to indoor dust-borne BBzP, DBP,
and the metabolites MBP and MEHP in urine from chil-
dren aged 3 to 9 years were associated with increased
risk of having allergy, asthma and related symptoms.
Prenatal urinary BPA was associated with increased odds
of wheezing in early life [33].
The Geometric SDs of urinary levels of phthalates and
BPA metabolites in the morning were higher than those
in the afternoon. These results may be associated with
the time at which the children performed certain activ-
ities. The urinary metabolite levels in the morning may
Table 2 Correlation between atopic dermatitis symptom
manifestation rate (ASMR) and metabolites of phthalates and
bisphenol A
ASMR MEHHP MEOHP MnBP BPA
ASMR 1
MEHHP −0.0909 1
MEOHP 0.0445 0.9165c 1
MnBP 0.1578a 0.7111c 0.7785c 1
BPAG 0.1566a 0.2039b 0.2634c 0.4243c 1




BPAG: Bisphenol A glucuronide
ap-value < 0.05, bp-value < 0.01, cp-value < 0.001 (extremely significant)
Table 3 Adjusted odds ratios (95% CI) between atopic dermatitis symptoms and urine concentration of phthalates and
bisphenol A metabolites
Metabolite Lagb 0 Lag 1 Lag 2 Lag 3
aORa 95%CI aOR 95%CI aOR 95%CI aOR 95%CI
MEHHP 1.21 0.47 3.07 1.46 0.57 3.70 1.82 0.71 4.66 2.13 0.82 5.53
MEOHP 2.28 0.74 7.00 1.96 0.75 5.10 3.11 1.01 9.61 2.98 0.96 9.27
MnBP 2.85 1.12 7.26 2.74 1.21 6.20 2.02 0.82 4.97 1.71 0.69 4.21
BPAG 1.79 0.91 3.52 2.01 1.08 3.74 1.63 0.84 3.19 1.53 0.78 2.98
aaOR: Adjusted for temperature, humidity, and season
bLag x: Effect of urine concentration of phthalates and bisphenol A metabolites x day(s) ahead on atopic dermatitis symptoms
Kim et al. Environmental Health  (2017) 16:24 Page 5 of 8
reflect more exposure to phthalates at home than that in
the day care center, while those in the afternoon may
reflect exposure at day care centers when considering
the half-life of phthalates in body. Most orally-administered
phthalates and BPA are systemically absorbed and excreted
in urine. The elimination half-lives for secondary me-
tabolites of DEHP such as MEOHP and MEHHP have
been estimated as 10–24 hours in healthy male vo-
lunteers; after 24 hours, 67.0% of the DEHP dose was
excreted in urine [22, 30].
The p-values for the correlations listed in Table 2 were
significant for all metabolites. As expected [4, 13, 24],
the secondary metabolites (MEHHP and MEOHP) were
strongly correlated each other. Note that each metabolite
of phthalates has a different phthalate exposure source.
The strong correlations between phthalate metabolites
imply that the children in our study are exposed to a
mixture of phthalates every day. The correlations among
the primary metabolite of DnBP (MnBP) and secondary
metabolites of DEHP (MEHHP and MEOHP) were also
strong, which also indicates the use of mixtures of
phthalates in products [5].
This study has limitations in that exposure and health
outcome are not individually matched. Urinary levels of
metabolites from pooled urine have been used for studies
of environmental exposure assessment in previous studies
[14–16, 38, 45, 47]. Our measurement of exposures to
phthalates and BPA metabolites for over a year in a lim-
ited population of children sharing the same space and life
style during the day may provide a rationale for a time
series analysis of risk factors for the manifestation of AD
symptom aggravation. Geometric SDs of the metabolite
level were narrow, reflecting a relatively small range of
variability between individuals. Despite the relatively small
number of subjects, repeated measures of exposure and
health outcome over one year period by a simple but con-
sistent method yielded statistical significance.
To our knowledge, this is the first longitudinal study to
report an association between urinary phthalates and BPA
concentrations and AD symptoms in children based on
daily measurements. This study includes long-term AD
symptom records and urine biomarker levels covering four
consecutive seasons, which enabled us to assess the expos-
ure to phthalates and BPA by season and time lag effects.
The results of this study provide evidence that exposure to
EDCs such as phthalates and BPA can be a risk factor for
AD symptom aggravation, demonstrating that to reduce
AD symptoms, children with AD should be prevented from
exposure to phthalates and BPA from plasticized products.
Conclusion
Our study results suggest that exposure to phthalates and
BPA is a risk factor for AD symptom aggravation in chil-
dren. As plasticized products have become ubiquitous in
homes and day care centers, more efforts are required to
reduce exposure to phthalates and BPA to avoid aggra-
vation of AD symptoms, especially in children. Further
studies on sources and assessment of EDC exposure
in children, especially regarding socioeconomic status
and time-activities are required to better understand
the effect of EDCs on AD and to devise strategies to
reduce their intake.
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